Attorney Docket No.: 14014.0410U1 U.S. Application Serial No.: 10/517,898 Sheet 1 of 1

JUL 2 7 2007

NFORMATION DISCLOSURE STATEMENT LIST

Complete if Known
Application Number 10/517,898
Filing Date 14 June 2002
First Named Inventor Warren Strober
Group Art Unit 2123
Examiner Name Unassigned

(Use as many sheets as necessary)

				Examiner Name			Unassigned		
U.S. PATENT DOCUMENTS									
Examiner's Initials	Cite No.	Document No.	Date		Name	Class	Subclass	Filing Date (	
					·	<del> </del>			
					1811-181-181-1-1-1-1-1-1-1-1-1-1-1-1-1-				
<del></del>	<u> </u>	FOF	REIGN PATE	NT C	OCUMENTS				
Examiner's nitials	Cite No.	Foreign Patent Document Country Code-Number-	Date		Name		Translation Yes/No		
	C1	WO 03/080675	2 Oct 2003	3	Dunlop et al.		Y		
	C2	WO 01/82960	8 Nov 200		Zeng, D.		Υ		
	C3	WO 00/64944	2 Nov 2000		Gyure, B		Υ		
		N	ON-PATEN	T DO	CUMENTS				
Examiner's nitials	Cite No.	No. Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)							
	Bost et al. "In vivo treatment with anti-interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice Immunol. 87:633-64 (1996)								
	C5	Chiaramonte et al. "IL-13 is a key regulator cytokine for Th2 cell-mediated							
			y granuloma rormation and IgE responses induced by S. mansoni						
		eggs" <i>J. Immunol.</i> 162(2):920-930 (1999)							
	C6	Grünig et al. "Requirement for IL-13 independently of IL-4 in experimental asthma" Science 282:2261-2263 (18 Dec 1998)							
	C7* Hans et al. "Interleukin 12 induced interferon-y increases inflamma dextran sulfate sodium induced colitis in mice" Eur. Cytokine Netw (March 2000)								
	C8*	Shalaby et al. "In vivo augmentation of natural killer activity by combined treatment with recombinant gamma interferon and Interleukin-2" J Interferon Research 5:571-581 (1985)							
	C9	Verdú et al. "Mo colitis" <i>Am J Ph</i> y						experimenta	
			T T		A4.	00/000	7		
Examiner	Signature	: /Ilia Ouspenski/	Date Cons	idered	l: U1/	02/200	9 		

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.